Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Sausville
E A
EA
Developmental Therapeutics Program, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20852, USA. sausville@nih.gov
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D016227:Benzoquinones; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D004357:Drug Synergism; D018841:HSP90 Heat-Shock Proteins / Q000187:drug effects / Q000502:physiology; D006801:Humans; D047029:Lactams, Macrocyclic; D016160:Retinoblastoma Protein / Q000187:drug effects / Q000502:physiology; D017828:Rifabutin / Q000031:analogs & derivatives / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000972:Antineoplastic Agents, Phytogenic; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D016160:Retinoblastoma Protein; D017828:Rifabutin; C112765:tanespimycin